# Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

> **NCT02957929** · PHASE1 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 46 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** APX001 single IV dose
- **DRUG:** APX001 single oral dose 1
- **DRUG:** APX001 single oral dose 2
- **DRUG:** APX001 single oral dose 3
- **DRUG:** APX001 single oral dose fasted
- **DRUG:** APX001 single oral dose fed
- **DRUG:** APX001 multiple oral doses 1
- **DRUG:** APX001 multiple oral doses 2
- **DRUG:** APX001 multiple oral doses 3
- **DRUG:** Cytochrome P450 substrates
- **DRUG:** Matching placebo control

## Key facts

- **NCT ID:** NCT02957929
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-31
- **Primary completion:** 2017-04-20
- **Final completion:** 2017-04-20
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957929, "Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02957929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*